Pembrolizumab Plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.
0
0 comments